In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
Caredx Inc (NASDAQ: CDNA) closed the day trading at $17.22 down -8.89% from the previous closing price of $18.9. In other words, the price has decreased by -$8.89 from its previous closing price. On the day, 1.13 million shares were traded. CDNA stock price reached its highest trading level at $18.615 during the session, while it also had its lowest trading level at $17.2.
Ratios:
For a better understanding of CDNA, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.56 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 23.88. For the most recent quarter (mrq), Quick Ratio is recorded 2.75 and its Current Ratio is at 3.03. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.07.
Wells Fargo Upgraded its Underweight to Equal Weight on January 15, 2025, whereas the target price for the stock was revised from $28 to $24.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 04 ’25 when Novack Jeffrey Adam sold 7,293 shares for $19.17 per share. The transaction valued at 139,804 led to the insider holds 97,925 shares of the business.
JEFFREY NOVACK bought 7,293 shares of CDNA for $137,473 on Dec 04 ’25. On Nov 07 ’25, another insider, Novack Jeffrey Adam, who serves as the Secretary and General Counsel of the company, sold 2,688 shares for $15.52 each. As a result, the insider received 41,723 and left with 105,218 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CDNA now has a Market Capitalization of 916568000 and an Enterprise Value of 719097024. As of this moment, Caredx’s Price-to-Earnings (P/E) ratio for their current fiscal year is 14.44. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.47 while its Price-to-Book (P/B) ratio in mrq is 2.85. Its current Enterprise Value per Revenue stands at 2.009 whereas that against EBITDA is -49.012.
Stock Price History:
The Beta on a monthly basis for CDNA is 2.51, which has changed by -0.20016927 over the last 52 weeks, in comparison to a change of 0.1877265 over the same period for the S&P500. Over the past 52 weeks, CDNA has reached a high of $25.95, while it has fallen to a 52-week low of $10.96. The 50-Day Moving Average of the stock is -2.75%, while the 200-Day Moving Average is calculated to be 5.28%.
Shares Statistics:
Over the past 3-months, CDNA traded about 949.95K shares per day on average, while over the past 10 days, CDNA traded about 630140 shares per day. A total of 51.41M shares are outstanding, with a floating share count of 46.25M. Insiders hold about 10.08% of the company’s shares, while institutions hold 97.10% stake in the company. Shares short for CDNA as of 1765756800 were 6260094 with a Short Ratio of 6.59, compared to 1763078400 on 6961045. Therefore, it implies a Short% of Shares Outstanding of 6260094 and a Short% of Float of 12.47.
Earnings Estimates
Currently, 6.0 analysts are dedicated to thoroughly evaluating and rating the performance of Caredx Inc (CDNA) in the stock market.The consensus estimate for the next quarter is $0.21, with high estimates of $0.26 and low estimates of $0.16.
Analysts are recommending an EPS of between $0.72 and $0.67 for the fiscal current year, implying an average EPS of $0.69. EPS for the following year is $0.89, with 6.0 analysts recommending between $1.1 and $0.76.
Revenue Estimates
8 analysts predict $102.58M in revenue. The current quarter. It ranges from a high estimate of $103.13M to a low estimate of $102M. As of . The current estimate, Caredx Inc’s year-ago sales were $86.58MFor the next quarter, 8 analysts are estimating revenue of $100.61M. There is a high estimate of $101.85M for the next quarter, whereas the lowest estimate is $97.89M.
A total of 8 analysts have provided revenue estimates for CDNA’s current fiscal year. The highest revenue estimate was $374.55M, while the lowest revenue estimate was $373.4M, resulting in an average revenue estimate of $374M. In the same quarter a year ago, actual revenue was $333.79MBased on 8 analysts’ estimates, the company’s revenue will be $417.65M in the next fiscal year. The high estimate is $428.3M and the low estimate is $399.2M.
